SCHEMBL4504615

SCHEMBL4504615

COc1[c]c(=O)n(C)nc1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.33
HPGD P15428 2/20 0.33
GAA P10253 2/20 0.33
KDM4E B2RXH2 1/20 0.33
GLA P06280 1/20 0.33
CASP1 P29466 1/20 0.33
HTT P42858 1/20 0.33
CASP7 P55210 1/20 0.33
ATM Q13315 1/20 0.33
HSD17B10 Q99714 1/20 0.33
HIF1A Q16665 1/20 0.32
KAT2B Q92831 1/20 0.32
BRD9 Q9H8M2 1/20 0.32
PLK1 P53350 1/20 0.32
CSNK2A1 P68400 1/20 0.32
PLK3 Q9H4B4 1/20 0.32
AADAT Q8N5Z0 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2038239 0.67
SCHEMBL14844549 0.65 ALDH1A1 (0.56) ALDH1A1HPGDGAAKDM4EHTT
SCHEMBL14844575 0.65 NPBWR1 (0.43) ALDH1A1HPGDGAAHTTKAT2B
SCHEMBL746830 0.64 CYP1A1 (0.36)
SCHEMBL10955786 0.64 CYP2C9 (0.38) KDM4E
SCHEMBL979263 0.62 HTR3A (0.38) ALDH1A1HPGDHTTATMKMT2A
SCHEMBL22016864 0.61 ALDH1A1 (0.41) ALDH1A1HPGDGAAKDM4EGLA
SCHEMBL466352 0.60 ALDH1A1 (0.55) ALDH1A1HPGDGAAATMKAT2B
SCHEMBL4498149 0.60 RAB9A (0.55) ALDH1A1HPGDGAAKDM4EGLA
SCHEMBL15150639 0.58

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7618983-B2 Bicyclic triazole α4 integrin inhibitors JANSSEN PHARMACEUTICA, N.V. (BE) 2009-11-17 US claimed
US-20060128748-A1 Bicyclic triazole alpha4 integrin inhibitors JANSSEN PHARMACEUTICA, N.V. (BE) 2006-06-15 US claimed
US-7618983-B2 Bicyclic triazole α4 integrin inhibitors JANSSEN PHARMACEUTICA, N.V. (BE) 2009-11-17 US disclosed
US-20060128748-A1 Bicyclic triazole alpha4 integrin inhibitors JANSSEN PHARMACEUTICA, N.V. (BE) 2006-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128748-A1 Bicyclic triazole alpha4 integrin inhibitors ITGA4, ITGB4, ITGB5 ALDH1A1 1568/4885HPGD 4297/4885GAA 4045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.